Nitrazepam Lph (Nitrazepam)

Nitrazepam binds to a specific site on the GABAA receptor complex and acts as a positive allosteric modulator. This increases the frequency of chloride ion channel opening when GABA binds, leading to greater neuronal inhibition. The resulting central nervous system depression produces the drug’s hypnotic, anxiolytic, and anticonvulsant effects.

The appropriate dose of nitrazepam is determined individually by a qualified prescriber based on the patient’s condition, age, renal and hepatic function, and response to therapy. Dosage regimens are not standardized in public information and should always follow the prescribing clinician’s instructions.

Limited clinical data are available on the safety of nitrazepam during pregnancy and lactation. Because benzodiazepines can cross the placenta and appear in breast milk, they are generally avoided unless the potential benefit outweighs the risk. Healthcare providers should assess each case carefully before prescribing to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nitrazepam has a relatively long half‑life compared with some short‑acting benzodiazepines such as lorazepam, which can result in prolonged sedation and a higher potential for accumulation in elderly patients. Its potency for hypnotic effect is comparable to temazepam, but clinicians often select agents based on the specific indication, duration of action needed, and patient tolerance.

Nitrazepam Lph tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in areas with excessive heat or humidity, and keep out of reach of children.

Nitrazepam is administered orally, typically as a tablet taken with a glass of water. The dose is usually taken once daily at bedtime for insomnia or as directed by the prescriber for anxiety or seizure control. Patients should follow the exact instructions provided by their healthcare professional.

Serious risks include respiratory depression, especially when combined with other central nervous system depressants, severe allergic reactions, profound sedation leading to falls or accidents, mood alterations such as depression or suicidal thoughts, and the development of physical dependence, tolerance, or withdrawal symptoms after prolonged use.

Nitrazepam is contraindicated in individuals with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and those who are currently abusing alcohol or other depressant substances. Caution is also advised for patients with severe hepatic impairment, myasthenia gravis, or a history of severe depression or suicidal behavior.